BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II
BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...
BridgeBio oncology spinout to go public in blank-check merger
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased federal oversight.
BridgeBio price target raised to $46 from $45 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...